Catalent entered a collaboration with Lisata to evaluate certepetide and analogs as payloads for antibody‑drug conjugates (ADCs), in a pact that could deliver up to $10 million in study initiation milestones plus future sales participation. Catalent will test whether iRGD‑derived cyclic peptides enhance tumor penetration and payload delivery when incorporated into its SMARTag site‑specific conjugation platform. The agreement leverages Lisata’s clinical momentum with certepetide and Catalent’s bioconjugation expertise to explore a new ADC payload class for hard‑to‑treat tumors.